Introduction

Company Overview

Speclipse, Inc. has developed a transformative, patented technology for real-time, non-invasive, in-vivo cancer diagnosis utilizing laser spectroscopy and machining learning algorithms.

Clinical trials in the United States, Australia, and South Korea have shown a skin-cancer diagnostic accuracy rate of greater than 90%, higher than any other competing technologies that have attempted to achieve a similar clinical outcome. Diagnostic tools presently used by physicians such as dermascopes or confocal microscopes, provide 60-70% accuracy, far below that of Spectra-Scope®.

Speclispe, Inc. has acquired ISO134485 certification for its manufacturing facility, and Specta-Scope® is on-track, expected to obtain CE mark and TGA approval in early 2019.  

About Us

Speclipse was founded by three Stanford University graduates and a dermatologist in November 2015, and currently has offices in Silicon Valley, California and South Korea. Speclipse’s technology was first developed in conjunction with a South Korean national lab, KIMM (Korea Institute of Machinery and Materials), and Seoul National University Hospital. Speclipse raised $3M in November 2016 and is planning for commercial launch of their Spectra-Scope® product in 2019.

Spectra-Scope

Core Technology

Speclipse’s core diagnostic technology is available in two models.  Spectra-Scope® is an “add-on module” which can be attached to existing aesthetic lasers at dermatology or primary care clinics to provide instant skin cancer diagnosis. The second diagnostic model offered is a “stand-alone” system which can be used without any additional equipment or accessories. It can be used by medical or cosmetic clinics who do not have existing laser equipment, or who prefer a small, portable stand-alone device for real-time diagnosis.

Due to the instantaneous nature and high-accuracy results provided by this technology, it is valuable for use in pathology labs for diagnosing biopsy samples, and beneficial for real-time diagnosis during oncological surgeries as well. 

Besides its outstanding clinical benefit, Spectra-Scope’s® size and portability make it uniquely qualified to address the unmet need for a technology which provides diagnostic accuracy and real-time results, with a cost-effective and minimal footprint.  

Team

Core Members

Advisory Board

Contact

Korea Office

Markcity Orange #502

123, Unjung-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

US Office

310 De Guigne Dr
Sunnyvale, California 94085 USA

For any inquiries, 

Please call or e-mail us:

+82-31-698-2269